The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
Open accessAbstract
Purpose: We investigated the global gene expression in a large panel of pancreatic endocrine tumors (PETs) aimed at identifying new potential targets for therapy and biomarkers to predict patient outcome. Patients and Methods: Using a custom microarray, we analyzed 72 primary PETs, seven matched metastases, and 10 normal pancreatic samples. Relevant differentially expressed genes were validated by either quantitative real-time polymerase chain reaction or immunohistochemistry on tissue microarrays. Results: Our data showed that: tuberous sclerosis 2 (TSC2) and phosphatase and tensin homolog (PTEN) were downregulated in most of the primary tumors, and their low expression was significantly associated with shorter disease-free and overall survival; somatostatin receptor 2 (SSTR2) was absent or very low in insulinomas compared with nonfunctioning tumors; and expression of fibroblast growth factor 13 (FGF13) gene was significantly associated with the occurrence of liver metastasis and shorter disease-free survival. TSC2 and PTEN are two key inhibitors of the Akt/mammalian target of rapamycin (mTOR) pathway and the specific inhibition of mTOR with rapamycin or RAD001 inhibited cell proliferation of PET cell lines. Conclusion: Our results strongly support a role for PI3K/Akt/mTOR pathway in PET, which ties in with the fact that mTOR inhibitors have reached phase III trials in neuroendocrine tumors. The finding of differential SSTR expression raises the potential for SSTR expression to be evaluated as a marker of response to somatostatin analogs. Finally, we identified FGF13 as a new prognostic marker that predicted poorer outcome in patients who were clinically considered free from disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
The Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 821
Metastasis genes: A progression puzzle
Bernards, R., & Weinberg, R. A. (2002) · Nature · doi:10.1038/418823a · Cited by 798
Shah, O. J., Wang, Z., & Hunter, T. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 798
The Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification
KLÖPPEL, G., PERREN, A., & HEITZ, P. U. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.002 · Cited by 794
PTEN: One Gene, Many Syndromes
Eng, C. (2003) · Human Mutation · doi:10.1002/humu.10257 · Cited by 787
Yao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., Gupta, S., Jacobs, C., Mares, J. E., Landgraf, A. N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7858 · Cited by 649
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
Zhang, H., Cicchetti, G., Onda, H., Koon, H. B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C. L., & Kwiatkowski, D. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17222 · Cited by 538
Regulation of pancreatic β-cell growth and survival by the serine/threonine protein kinase Akt1/PKBα
Tuttle, R. L., Gill, N. S., Pugh, W., Lee, J.-P., Koeberlein, B., Furth, E. E., Polonsky, K. S., Naji, A., & Birnbaum, M. J. (2001) · Nature Medicine · doi:10.1038/nm1001-1133 · Cited by 511
Pape, U., Jann, H., Müller‐Nordhorn, J., Bockelbrink, A., Berndt, U., Willich, S. N., Koch, M., Röcken, C., Rindi, G., & Wiedenmann, B. (2008) · Cancer · doi:10.1002/cncr.23549 · Cited by 405
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR
Zhang, H., Bajraszewski, N., Wu, E., Wang, H., Moseman, A. P., Dabora, S. L., Griffin, J. D., & Kwiatkowski, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28984 · Cited by 381
Population-Based Study of Islet Cell Carcinoma
Yao, J. C., Eisner, M. P., Leary, C., Dagohoy, C., Phan, A., Rashid, A., Hassan, M., & Evans, D. B. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9566-6 · Cited by 338
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., Le, L., Oza, A., Nicklee, T., Ho, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603419 · Cited by 317
Olsen, S. K., Garbi, M., Zampieri, N., Eliseenkova, A. V., Ornitz, D. M., Goldfarb, M., & Mohammadi, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303183200 · Cited by 292
Human Pancreatic Islets Produce and Secrete MCP-1/CCL2: Relevance in Human Islet Transplantation
Piemonti, L., Leone, B. E., Nano, R., Saccani, A., Monti, P., Maffi, P., Bianchi, G., Sica, A., Peri, G., Melzi, R., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.1.55 · Cited by 287
Self-citationPerren, A., Komminoth, P., Saremaslani, P., Matter, C., Feurer, S., Lees, J. A., Heitz, P. U., & Eng, C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64624-x · Cited by 266
Couvelard, A., O'Toole, D., Turley, H., Leek, R., Sauvanet, A., Degott, C., Ruszniewski, P., Belghiti, J., Harris, A. L., Gatter, K., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602245 · Cited by 257
PTEN Induces Cell Cycle Arrest by Decreasing the Level and Nuclear Localization of Cyclin D1
Radu, A., Neubauer, V., Akagi, T., Hanafusa, H., & Georgescu, M.-M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.17.6139-6149.2003 · Cited by 221
Bettini, R., Boninsegna, L., Mantovani, W., Capelli, P., Bassi, C., Pederzoli, P., Delle Fave, G. F., Panzuto, F., Scarpa, A., & Falconi, M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm552 · Cited by 213
Self-citationRachdi, L., Balcazar, N., Osorio-Duque, F., Elghazi, L., Weiss, A., Gould, A., Chang-Chen, K. J., Gambello, M. J., & Bernal-Mizrachi, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803047105 · Cited by 209
Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors
Marion-Audibert, A.-M., Barel, C., Gouysse, G., Dumortier, J., Pilleul, F., Pourreyron, C., Hervieu, V., Poncet, G., Lombard‐Bohas, C., Chayvialle, J., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01198-3 · Cited by 164
Hansel, D. E., Rahman, A., House, M., Ashfaq, R., Berg, K., Yeo, C. J., & Maitra, A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0285 · Cited by 164
Zitzmann, K., De Toni, E. N., Brand, S., Göke, B., Meinecke, J., Spöttl, G., Meyer, H. H. D., & Auernhammer, C. J. (2007) · Neuroendocrinology · doi:10.1159/000100057 · Cited by 160
Rigaud, G., Missiaglia, E., Moore, P. S., Zamboni, G., Falconi, M., Talamini, G., Pesci, A., Baron, A., Lissandrini, D., Rindi, G., et al. (2001) · PubMed · Cited by 150
Self-citationGrozinsky‐Glasberg, S., Franchi, G. M., Teng, M. J., Leontiou, C. A., de Oliveira, A. R., Ciaramella, P. D., Salahuddin, N., Korbonits, M., & Grossman, A. B. (2007) · Neuroendocrinology · doi:10.1159/000111501 · Cited by 142
Panzuto, F., Fonzo, M. D., Iannicelli, E., Sciuto, R., MAINI, C. L., Capurso, G., Milione, M., Cattaruzza, M. S., Falconi, M., David, V., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj113 · Cited by 138
Self-citationMutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors
Bartsch, D. K., Hahn, S. A., Danichevski, K. D., Ramaswamy, A., Bastian, D., Galehdari, H., Barth, P. J., Schmiegel, W., Simon, B., & Rothmund, Μ. (1999) · Oncogene · doi:10.1038/sj.onc.1202585 · Cited by 130
Schoorlemmer, J., & Goldfarb, M. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205520200 · Cited by 128
Ma, L., Teruya‐Feldstein, J., Behrendt, N., Chen, Z., Noda, T., Hino, O., Cordon‐Cardo, C., & Pandolfi, P. P. (2005) · Genes & Development · doi:10.1101/gad.1314405 · Cited by 121
Capurso, G., Lattimore, S., Crnogorac‐Jurcevic, T., Panzuto, F., Milione, M., Bhakta, V., Campanini, N., Swift, S. M., Bordi, C., Fave, G. D., et al. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01153 · Cited by 115
Self-citationRole of disease‐causing genes in sporadic pancreatic endocrine tumors: MEN1 andVHL
Moore, P. S., Missiaglia, E., Antonello, D., Zamò, A., Zamboni, G., Corleto, V. D., Falconi, M., & Scarpa, A. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1180 · Cited by 112
Self-citationThe genetic basis of tuberous sclerosis
Young, J., & Povey, S. (1998) · Molecular Medicine Today · doi:10.1016/s1357-4310(98)01245-3 · Cited by 112
Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood
Verhoef, S., van Diemen-Steenvoorde, R., Akkersdijk, W. L., Bax, N. M. A., Ariyürek, Y., Hermans, C. J., van Nieuwenhuizen, O., Nikkels, P. G. J., Lindhout, D., Halley, D. J. J., et al. (1999) · European Journal of Pediatrics · doi:10.1007/s004310051073 · Cited by 110
Butturini, G., Bettini, R., Missiaglia, E., Mantovani, W., Dalai, I., Capelli, P., Ferdeghini, M., Pederzoli, P., Scarpa, A., & Falconi, M. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01200 · Cited by 98
Self-citationDuerr, E., Mizukami, Y., Ng, A., Xavier, R. J., Kikuchi, H., Deshpande, V., Warshaw, A. L., Glickman, J. N., Kulke, M. H., & Chung, D. C. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0194 · Cited by 97
Chung, D. C., Brown, S. B., Graeme‐Cook, F., Tillotson, L. G., Warshaw, A. L., Jensen, R. T., & Arnold, A. (1998) · PubMed · Cited by 97
Fazio, N., de Braud, F., Fave, G. D., & Öberg, K. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl144 · Cited by 95
Kaper, F., Dornhöfer, N., & Giaccia, A. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3375 · Cited by 94
Maitra, A., Hansel, D. E., Argani, P., Ashfaq, R., Rahman, A., Naji, A., Deng, S., Geradts, J., Hawthorne, L., House, M. G., et al. (2003) · PubMed · Cited by 93
Perren, A., Wiesli, P., Schmid, S., Montani, M., Schmitt, A., Schmid, C., Moch, H., & Komminoth, P. (2006) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200608000-00018 · Cited by 84
Beghelli, S., Pelosi, G., Zamboni, G., Falconi, M., Iacono, C., Bordi, C., & Scarpa, A. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199809)186:1<41::aid-path172>3.0.co;2-l · Cited by 82
Self-citationMalignant Pancreatic Endocrine Tumor in a Child With Tuberous Sclerosis
Francalanci, P., Diomedi‐Camassei, F., Purificato, C., Santorelli, F. M., Giannotti, A., Dominici, C., Inserra, A., & Boldrini, R. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200310000-00012 · Cited by 81
Couvelard, A., Hu, J., Steers, G., O’Toole, D., Sauvanet, A., Belghiti, J., Bédossa, P., Gatter, K. C., Ruszniewski, P. B., & Pezzella, F. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.007 · Cited by 79
Negative Regulation of TSC1-TSC2 by Mammalian D-Type Cyclins
Zacharek, S. J., Xiong, Y., & Shumway, S. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2236 · Cited by 72 · cited 1×
“This latter observation is also important, since PTEN mutation or downregulation as well as Akt activation are responsible for the overexpression of cyclin D1,(41) which negatively regulates TSC1-TSC2 function.(42) It has been shown that lack of TSC2 expression induces impaired PI3K-Akt activation by reducing platelet…”
BackgroundFrequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours
Ss, G., Wu, X., Shimoide, A. T., Wong, J., Moatamed, F., & Sawicki, M. P. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1790073 · Cited by 53
Bloomston, M., Durkin, A. J., Yang, I. V., Rojiani, M. V., Rosemurgy, A. S., Enkmann, S., Yeatman, T. J., & Zervos, E. E. (2004) · Annals of Surgical Oncology · doi:10.1245/aso.2004.03.077 · Cited by 48
Dpc4 is expressed in virtually all primary and metastatic pancreatic endocrine carcinomas
Scarpa, A., Orlandini, S., Moore, P. S., Lemoine, N. R., Beghelli, S., Baron, A., Falconi, M., & Zamboni, G. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-001-0569-6 · Cited by 14
Self-citationEvaluating the activity of temsirolimus in neuroendocrine cancer
O’Donnell, P. H., & Ratain, M. J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603513 · Cited by 8
Cited by
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Jiao, Y., Shi, C., Edil, B. H., de Wilde, R. F., Klimstra, D. S., Maitra, A., Schulick, R. D., Tang, L. H., Wolfgang, C. L., Choti, M. A., et al. (2011) · Science · doi:10.1126/science.1200609 · Cited by 1,717
Pavel, M. E., Hainsworth, J. D., Baudin, E., Peeters, M., Hörsch, D., Winkler, R. E., Klimovsky, J., Lebwohl, D., Jehl, V., Wolin, E. M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61742-x · Cited by 1,058
Whole-genome landscape of pancreatic neuroendocrine tumours
Initiative, A. P. C. G., Scarpa, A., Chang, D. K., Nones, K., Corbo, V., Patch, A.-M., Bailey, P., Lawlor, R. T., Johns, A. L., Miller, D. K., et al. (2017) · Nature · doi:10.1038/nature21063 · Cited by 999
Self-citationPavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Metadata
- Authors
- Missiaglia, E., Dalai, I., Barbi, S., Beghelli, S., Falconi, M., della Peruta, M., Piemonti, L., Capurso, G., Di Florio, A., delle Fave, G., Pederzoli, P., Croce, C. M., & Scarpa, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-01-10
- Volume
- 28
- Issue
- 2
- Pages
- 245-255
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160531384
- Cited by
- 536
- References
- 53
- FWCI
- 22.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.